Wells Fargo lowered the firm’s price target on Viridian Therapeutics (VRDN) to $26 from $27 and keeps an Equal Weight rating on the shares. The firm thinks shares will remain range bound in the near term ahead of key catalysts in 2026, and sees little upside on VRDN-006 Phase 1 data in Q3 2025. That said, management continues to execute well and reiterated key timelines for veligrotug and VRDN-003, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments
- Viridian Therapeutics Reports Q2 2025 Financial Results
- Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements
- Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating
- Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments